HAE Stock Down -32% after 6-Day Loss Streak
Haemonetics (HAE) stock hit day 6 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -32% return. The company has lost about $796 Mil in value over the last 6 days, with its current market capitalization at about $2.5 Bil. The stock remains 33.1% below its value at the end of 2024. This compares with year-to-date returns of 9.6% for the S&P 500.
HAE provides medical products and solutions, including automated plasma collection devices, blood component systems, disposables, and related software across plasma, blood center, and hospital segments. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell HAE.
Comparing HAE Stock Returns With The S&P 500
The following table summarizes the return for HAE stock vs. the S&P 500 index over different periods, including the current streak:
- AST SpaceMobile: Is This Starlink Rival Stock Poised To Soar Higher?
- Where Is Alphabet Stock Headed?
- How To Earn 8.2% Yield While Waiting to Buy WYNN 30% Cheaper
- What Could Light a Fire Under Costco Wholesale Stock
- The Hidden Dangers Facing Amazon.com Stock
- Cash Rich, Low Price – Ardent Health Stock to Break Out?
| Return Period | HAE | S&P 500 |
|---|---|---|
| 1D | -0.5% | 1.1% |
| 6D (Current Streak) | -31.5% | 1.8% |
| 1M (21D) | -31.9% | 2.8% |
| 3M (63D) | -25.6% | 10.3% |
| YTD 2025 | -33.1% | 9.6% |
| 2024 | -8.7% | 23.3% |
| 2023 | 8.7% | 24.2% |
| 2022 | 48.3% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: HAE Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 84 S&P constituents with 3 days or more of consecutive gains and 40 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 43 | 25 |
| 4D | 23 | 14 |
| 5D | 10 | 0 |
| 6D | 1 | 1 |
| 7D or more | 7 | 0 |
| Total >=3 D | 84 | 40 |
Key Financials for Haemonetics (HAE)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $1.3 Bil | $1.4 Bil |
| Operating Income | $173.3 Mil | $201.2 Mil |
| Net Income | $117.6 Mil | $167.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $330.6 Mil | $321.4 Mil |
| Operating Income | $50.7 Mil | $53.9 Mil |
| Net Income | $58.0 Mil | $34.0 Mil |
The losing streak HAE stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.